Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: Approvals For Xultophy, Soliqua And Darzalex; NDAs From Intarcia And GSK; Complete Response For Green Cross

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker

Advertisement

Related Content

Keeping Track: A Lilly Breast Cancer Approval, A Couple Of CRLs, And A Plethora Of Priority Reviews
Boehringer Aims To Block GSK's Triple COPD Inhaler, Citing Combo Rule
VC Roundup: Infectious Disease Startup Snags $150m And Former Biogen CEO Scangos
US Approval Delay For Green Cross But Long Term Strategy Intact
Expanded US Approval Set To Take Janssen’s Darzalex Higher
Novo Nordisk, Sanofi Insulin Combo Products Clear US Regulatory Hurdles
Keeping Track: FDA Rejects Mealtime Insulin, Antihistamine; Misses Goal For Another Opioid
Intarcia Raises $215m As NDA For ITCA 650 Slips To Fourth Quarter
Keeping Track: Janssen Gets A Breakthrough Therapy Status, FDA Awards Two Orphan Drug Designations, Portola Lands A CRL
Keeping Track: Novartis, Calardius Pick Up Speed; ADMA Stumbles

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119581

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel